Clinical Trial Update: Can Aspirin Reduce the Risk of HCC in Cirrhosis: The AspiRe HCC Trial [Phase 3]

View source ↗

Summary

Phase 3 trial assessing whether aspirin can reduce the risk of hepatocellular carcinoma in patients with liver cirrhosis; the AspiRe HCC Trial is not yet recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Cirrhosis

Drugs mentioned

• Aspirin (Aspirin)

Snippet

Sponsor: Curtin University | Conditions: Liver Cirrhosis | Phase 3 | Status: NOT_YET_RECRUITING